Real world data on treatment of pediatric onset multiple sclerosis

In this issue Saponaro et al. present a longitudinal follow-up study in a real world setting in which they compared the efficacy and safety of disease modifying treatments (DMT) in children with multiple sclerosis (MS) from the French KID-BIOSEP cohort, including children with age of onset under 11 years [1]. The majority of children in this cohort initially started on traditional first line injectable treatment with interferon-beta. Notably, 77% of the children treated with interferon-beta switched during follow-up to second line treatment, whereas only 15% of the children first treated with newer DMT switched.